

## Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma

Sara De Dosso<sup>1</sup>, Vittoria Martin<sup>2</sup>, Elena Zanellato<sup>2</sup>, Milo Frattini<sup>2</sup>, and Piercarlo Saletti<sup>1</sup>

<sup>1</sup>Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;

<sup>2</sup>Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno, Switzerland

---

### ABSTRACT

---

There are no standard chemotherapeutic options for patients with squamous cell anal carcinoma, relapsing and progressing on palliative cisplatin-based regimens. Similarly to other malignant conditions, monoclonal antibodies directed against the epidermal growth factor receptor may represent an attractive therapeutic strategy. Here we describe a patient who, based on molecular profile, benefited from the combination of irinotecan and cetuximab. Free full text available at [www.tumorionline.it](http://www.tumorionline.it)

---

**Key words:** anal cancer, cetuximab, EGFR, K-Ras.

Correspondence to: Sara De Dosso, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.

Tel +41-091-811-7919;

fax +41-091-811-7916;

e-mail [Sara.Dedosso@eoc.ch](mailto:Sara.Dedosso@eoc.ch)

Received September 23, 2009;  
accepted January 29, 2010.